Edgen Stock·Sep 19 2025, 00:49Back
FDA Grants Breakthrough Therapy Designation for Daiichi Sankyo and Merck's Raludotatug Deruxtecan
Edgen Stock·Sep 19 2025, 00:49
[1] Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab (https://finance.yahoo.com/news/raludotatug-de ...)[2] MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer - Nasdaq (https://vertexaisearch.cloud.google.com/groun ...)[3] MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer - Zacks (https://vertexaisearch.cloud.google.com/groun ...)
